A phase 2 trial exploring the significance of homologous recombination status in patients with platinum sensitive or platinum resistant relapsed ovarian cancer receiving combination cediranib and olaparib
Joyce F. Liu(Duke University), Ursula A. Matulonis(Dana-Farber Cancer Institute), Andrea E. Wahner Hendrickson(Mayo Clinic in Arizona), David M. O’Malley(The Ohio State University), Madeline Polak(Dana-Farber Cancer Institute), Robert M. Wenham(Moffitt Cancer Center), Geoffrey I. Shapiro(Brigham and Women's Hospital), Mihaela Cristea(City Of Hope National Medical Center), Alexander Olawaiye(Magee-Womens Hospital), Niya Xiong(Dana-Farber Cancer Institute), S. Percy Ivy(National Cancer Institute), Nancy Chan(Unknown), Elizabeth M. Swisher(University of Washington), James L. Abbruzzese(Duke University), Richard T. Penson(Massachusetts General Hospital), Deborah K. Armstrong(Johns Hopkins University), Jung Min Lee(Kyung Hee University), Su–Chun Cheng, Koji Matsuo(University of Southern California), William T. Barry(Harvard University), Elise C. Kohn(National Cancer Institute)
Cited by 11
Related Papers
Anaplastic Lymphoma Kinase Inhibition in Non–Small-Cell Lung Cancer
|New England Journal of Medicine|2010|4.5k
Maintenance Olaparib in Patients with Newly Diagnosed Advanced Ovarian Cancer
|New England Journal of Medicine|2018|2.9k
Niraparib Maintenance Therapy in Platinum-Sensitive, Recurrent Ovarian Cancer
|New England Journal of Medicine|2016|2.5k